AnaCardio

📍 Solna, Sweden👥 23 employees💰 Last funded Jan 2025
Pharmaceutical Manufacturing🌐 anacardio.com
Website LinkedIn
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Sweden
1
Frequently asked questions
Who invested in AnaCardio?
AnaCardio has 2 investors on record on gritt.io.
When did AnaCardio last raise funding?
The most recent investment in AnaCardio recorded on gritt.io was in January 2025.
What industry is AnaCardio in?
AnaCardio operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is AnaCardio based?
AnaCardio is headquartered in Solna, Sweden.